Division of Clinical Research

Office of the Vice President and Innovation

The U.S. Food and Drug Administration (FDA) issued the draft guidance on September 23, 2019 on Patient Engagement in Design and Conduct of Medical Device Clinical Investigations.  

The U.S. Food and Drug Administration (FDA or the Agency) values the experience and perspectives of patients and their family caregivers. FDA believes that these individuals can and should be able to provide their insights about a disease or condition, including living with that disease/condition, and the impact of medical devices in the diagnosis, treatment, and management of the disease/condition, through engagement activities. Such activities can assist the Agency in understanding the patient experience, as well as sponsors as they design and conduct medical device clinical investigations.  (“Clinical investigation” is defined in 21 CFR 50.3(c) and 56.102(c).)

This draft guidance is intended to:

  1. help sponsors understand how they can use patient engagement to elicit experience, perspectives, and other relevant information from patient advisors (see definition in Section IV) to improve the design and conduct of medical device clinical investigations;
  2. highlight the benefits of engaging with patient advisors early in the medical device development process;
  3. illustrate which patient engagement activities are generally not considered by FDA to constitute research or an activity subject to FDA’s regulations, including regulations regarding institutional review boards (IRBs); and
  4. address common questions and misconceptions about collecting and submitting to FDA patient engagement information regarding the design and conduct of a medical device clinical investigation.

Categories FDA Regulatory, Policies & Guidance
Tagged , , ,

Follow this blog